To Evaluate Sperm Parameters in Men With Secondary Hypogonadism Previously Treated With Topical Testosterone

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Repros Therapeutics Inc.
ClinicalTrials.gov Identifier:
NCT00706719
First received: June 25, 2008
Last updated: July 22, 2015
Last verified: July 2015
  Purpose

The study was designed to determine if Androxal® would affect sperm parameters (count, concentration, volume) in men with secondary hypogonadism who have been previously treated with topical testosterone.


Condition Intervention Phase
Secondary Hypogonadism
Drug: 25 mg Androxal
Drug: Testim 1%
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Randomized, Open-Label, Fixed Dose, Active-Control, Multi-Center Phase IIB Study to Evaluate Fertility in Men With Secondary Hypogonadism, Comparing Androxal® to a Topical Testosterone in Men Previously Treated With Topical Testosterone.

Resource links provided by NLM:


Further study details as provided by Repros Therapeutics Inc.:

Primary Outcome Measures:
  • Sperm Concentration [ Time Frame: Baseline, Month 3, Month 6, Follow-Up (Month 7) ] [ Designated as safety issue: No ]
    Total sperm concentration was measured.

  • Motile Total Sperm Count [ Time Frame: Baseline, Month 3, Month 6, Follow-Up (Month 7) ] [ Designated as safety issue: No ]
    Motile total sperm count was measured.

  • Semen Volume [ Time Frame: Baseline, Month 3, Month 6, Follow-Up (Month 7) ] [ Designated as safety issue: No ]
    Semen volume was measured.


Secondary Outcome Measures:
  • Luteinizing Hormone (LH) Levels [ Time Frame: Baseline, Month 3, Month 6, Follow-Up (Month 7) ] [ Designated as safety issue: No ]
    LH levels were measured.

  • Follicle Stimulating Hormone (FSH) Levels [ Time Frame: Baseline, Month 3, Month 6, Follow-Up (Month 7) ] [ Designated as safety issue: No ]
    FSH levels were measured.


Enrollment: 17
Study Start Date: June 2008
Study Completion Date: August 2009
Primary Completion Date: July 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 25 mg Androxal no wash out
1 capsule daily for 6 months of 25 mg of Androxal in men without a 3 month wash out period
Drug: 25 mg Androxal
25 mg Androxal capsules, 1 capsule daily for 6 months
Other Name: Enclomiphene citrate
Active Comparator: Testim 1% (topical testosterone)
Testim 1% Gel applied topically for 6 months
Drug: Testim 1%
Testim 1% gel, dosage to be titrated according to manufacturer's instructions, once daily for 6 months
Other Name: Topical testosterone
Experimental: 25 mg Androxal wash out
1 x 25 mg Androxal capsule daily for 6 months in men with a previous 3 month washout period of topical testosterone
Drug: 25 mg Androxal
25 mg Androxal capsules, 1 capsule daily for 6 months
Other Name: Enclomiphene citrate

Detailed Description:

The study was designed to determine if Androxal® would affect sperm parameters (count, concentration, volume) in men with secondary hypogonadism who have been previously treated with topical testosterone. A maximum of twelve subjects per group were randomized to daily treatments of Androxal® or topical testosterone (Testim®) for six months. The protocol was later amended to include a treatment group who received Androxal after a 3 month wash out period.

  Eligibility

Ages Eligible for Study:   21 Years to 60 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Healthy adult males between 21 and 60 years of age who have been diagnosed with AIHH.
  • Subjects must have been treated with a topical testosterone replacement therapy (typically AndroGel® or Testim®) for at least 6 months at enrollment and for not more than 2 years.

Exclusion Criteria:

  • A history of idiopathic infertility due to primary hypogonadism, testicular failure, Kallmann's syndrome or any other infertility condition.
  • Subjects demonstrating any clinically significant medical condition rendering the subjects infertile or marginally fertile other than AIHH.
  • Men with a history of, known, or suspected prostate disease not ruled out by a prostate biopsy, or a prostate specific antigen (PSA)>3.6 or clinical suspicion of current prostate disease.
  • Men with a hematocrit in excess of 50 % or hemoglobin >17 g/dl
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00706719

Locations
United States, New York
University Urology Associates
New York, New York, United States, 10016
MAZE Labs
Purchase, New York, United States, 10577
Sponsors and Collaborators
Repros Therapeutics Inc.
Investigators
Study Director: Ronald Wiehle, PhD Repros Therapeutics Inc.
  More Information

No publications provided

Responsible Party: Repros Therapeutics Inc.
ClinicalTrials.gov Identifier: NCT00706719     History of Changes
Other Study ID Numbers: ZA-201
Study First Received: June 25, 2008
Results First Received: August 25, 2010
Last Updated: July 22, 2015
Health Authority: United States: Food and Drug Administration

Keywords provided by Repros Therapeutics Inc.:
Adult Onset Idiopathic Hypothalamic Hypogonadism (AIHH)
Secondary hypogonadism
Semen volume
Sperm count
Sperm motility

Additional relevant MeSH terms:
Hypogonadism
Neoplasm Metastasis
Endocrine System Diseases
Gonadal Disorders
Neoplasms
Neoplastic Processes
Pathologic Processes
Clomiphene
Enclomiphene
Methyltestosterone
Testosterone
Testosterone 17 beta-cypionate
Testosterone enanthate
Testosterone undecanoate
Zuclomiphene
Anabolic Agents
Androgens
Antineoplastic Agents
Antineoplastic Agents, Hormonal
Estrogen Antagonists
Estrogen Receptor Modulators
Fertility Agents
Fertility Agents, Female
Hormone Antagonists
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Pharmacologic Actions
Physiological Effects of Drugs
Reproductive Control Agents
Selective Estrogen Receptor Modulators

ClinicalTrials.gov processed this record on August 26, 2015